Healthcare News
What Is the Best Bariatric Surgery? Sleeve vs. Bypass vs. SIPS
Wondering which bariatric surgery is best for you? Compare sleeve gastrectomy, gastric bypass, and SIPS with expert guidance from Dr. Kudsi at UChicago | AdventHealth LaGrange, serving Naperville & Oak Brook.
Will Bariatric Surgery Cure Diabetes? Sleeve vs. Bypass vs. SIPS at UChicago | AdventHealth LaGrange
Can bariatric surgery cure diabetes? Discover how sleeve, bypass, and SIPS compare for Type 2 diabetes remission at UChicago | AdventHealth LaGrange, near Naperville, Oak Brook, and Downers Grove.
Inguinal hernia
Inguinal hernias are the commonest type of abdominal wall hernias (up to 80% 3) and are most often acquired. There is a recognised male predilection with an M:F ratio of up to 7:1 3.
Weight-loss injections can cause gallstones, warns pharmacist
A leading pharmacist has raised concerns over a rise in gallbladder issues among individuals using weight-loss injections, particularly Eli Lilly’s Mounjaro (tirzepatide).
Weight loss protects—even when weight is regained
The study, published in The Lancet Region Health—Europe, focuses on the health consequences of regaining some weight following significant weight loss, an area in which scientific knowledge is described as extremely limited.
Gastric bypass outperforms other surgeries in severe obesity treatment, trial shows
Gastric bypass is the most clinically and cost-effective form of interventional surgery for people living with severe obesity, reveals new research.
Salmonella, the insidious contributor to gallbladder and colon cancers
Salmonella infects hundreds of millions of people yearly, invading host cells and altering signalling pathways that can promote cancer.
Aspartate beta-hydroxylase is a prognostic factor in gallbladder cancer with the function of promoting tumorigenesis and chemoresistance
ASPH plays a role in promoting the development of gallbladder cancer and resistance to chemotherapeutic agents, rendering it a promising target for therapeutic interventions. Active therapeutic compounds targeted on ASPH can be identified among the active ingredients present in traditional Chinese medicine.
Tirzepatide produces clinically meaningful weight loss for at least 3 years in non-diabetic overweight adults: Trial
Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes
Weight-loss drugs may help patients ‘catch up’ if behavioral therapy fails
Adding an anti-obesity medication alongside behavioral therapy produced significantly more weight loss in patients who initially struggled with the therapy, a study in Nature Medicine showed.
